期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

硼替佐米治疗多发性骨髓瘤合并慢性肾衰竭6例 被引量：2

下载PDF
导出
摘要 肾功能不全是多发性骨髓瘤（multiple myeloma,MM）的常见并发症,但对于已转为慢性肾功能不全的患者,有关其治疗效果的报道尚少。现将我院2007-2010年应用硼替佐米治疗MM合并慢性肾衰竭6例患者的结果报道如下。
作者 刘默 曹志刚 周宏伟 杜瑜 彭朝津 杨清明
机构地区 解放军总医院第一附属医院老年肿瘤血液科
出处 《解放军医学杂志》 CAS CSCD 北大核心 2012年第4期390-390,共1页 Medical Journal of Chinese People's Liberation Army
关键词 多发性骨髓病 肾功能衰竭 慢性
分类号 R733.3 [医药卫生—肿瘤]
  • 相关文献

参考文献1

二级参考文献28

  • 1KARIN M,BENNERIAH Y.Phosphoryl-ation meets ubiquitination:the control of NF-κ B activity[J].Ann Rev Immunol,2000,18(1):621-663.
  • 2SAURAI H,SHIGEMORI N,HISADA Y,et al.Suppression of NF-kappa B and AP-1 activation by glucocorticoids in experimental glomerulonephritis in rats:molecular mechanisms of antinephritic action[J].Biochim Biophys Acta,1997,1362(3):252-262.
  • 3SAKURAI H,HISADA Y,UENO M,et al.Activation of transcription factor NF-kappa B in experimental glomerulonephritis in rats[J].Biochim Biophys Acta,1996,1316(2):132-138.
  • 4TOMITA N,MORISHITA R,LAN H Y,et al.In vivo administration of a nuclear transcription factor-kappaB decoy suppresses experimental crescentic glomerulonephritis[J].Jam Soc Nephro1,2000,11(7):1244-1252.
  • 5MEZZANO S A,BARRIA M,DROGUETT M A,et al.Tubular NF-kappa B and AP-1 activation in human proteinuric renal disease[J].Kidney Int,2001,60(4):1366-1377.
  • 6DRUMM K,GASSNER B,SILBERNAG S,et al.Albumin in the mg/L-range activates NF-kappa B in renal proximal tubule-derived cell lines via tyrosine kinases and protein kinase C[J].Eur J Med Res,2001,6(6):247-258.
  • 7LANG S,HARTNER A,STERZEL R B,et al.Requirement of cyclin D1 in mesangial cell mitogenesis[J].J Am Soc Nephrol,2000,11(8):1398-1408.
  • 8CHANDELK N S,SCHUMACKER P T,ARCH R H,et al.Reactive oxygen species are downstream products of TRAF mediated signal transduction[J].J Biol Chem,2001,276(46):42728-42736.
  • 9ESTEBAN V,LORENZO O,RUPEREZ M,et al.Angiotensin II,via AT1 and AT2 receptors and NF-kappaB pathway,regulates the inflammatory response in unilateral ureteral obstruction[J].J Am Soc Nephrol,2004,15(6):1514-1529.
  • 10CHADE A R,BENTEY M D,ZHU X,et al.Antioxidant intervention prevents renal neovascularization in hypercholest-erolemic pigs[J].J Am Soc Nephrol,2004,15(7):1816-1825.

共引文献3

同被引文献33

  • 1Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol, 2014, 15(12): e538-548.
  • 2Rajkumar SV, Haroussean JL, Durie B, et al. International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 [J]. Blood, 2011, 117(18): 4691-4695.
  • 3Paiva B, Gutierrez NC, Rosinol L, et al. High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma[J]. Blood, 2012, 119(3): 687- 691.
  • 4Rawstron AC, Child JA, de Tute RM, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study[J].J Clin Oncol, 2013, 31(20): 2540-2547.
  • 5Martinez-Lopez J, Lahuerta JJ, Pepin F, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma[J]. Blood, 2014, 123(20): 3073-3079.
  • 6Mikhael JR, Dingli D, Roy V, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013[J]. Mayo Clin Proc, 2013, 88(4): 360-376.
  • 7Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma [ J], Leukemia, 2014, 28 (2): 269- 277.
  • 8Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group [J]. J Clin Oncol, 2015, 33 (26): 2863-2869.
  • 9Jakubowiak AJ, Siegel DS, Martin T, et al. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study[J]. Leukemia, 2013, 27(12): 2351-2356.
  • 10Moreau P, Avet-Loiseau H, Harousseau JL, et al. Current trends in autologous stem cell transplantation for myeloma in the era of novel therapies[J].J Clin Oncol, 2011, 29(14): 1898-1906.

引证文献2

二级引证文献10

解放军医学杂志
2012年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部